Press release Valby, 18 May 2018 Potential new treatment for schizophrenia and Alzheimer's disease starts first phase of clinical testing. H. Lundbeck A/S (Lundbeck) starts the clinical development of a potential new treatment of schizophrenia and Alzheimer's disease.

HIGHLIGHTS Revenue reached DKK 4,585 million in the first quarter of 2018 representing an increase of 9% (14% in local currencies) compared to the same period in 2017 Revenue of Abilify Maintena ® increased 15% to DKK 364 million (23% in local currencies) Revenue of Brintellix ® /Trintellix ®

Trintellix (vortioxetin) er den første FDA godkendte antidepressiv, der har data in indlægsseddlen, der viser positiv effekt på proceshastighed, et aspekt af kognitiv funtionsevne der er hæmmet hos mange patienter med akut depression Svær depression er blandt de førende årsager til

Trintellix ® (vortioxetine) is the first FDA-approved treatment for MDD to have data in the U.S. Prescribing Information showing a positive effect on processing speed, an aspect of cognitive function that is impaired in many patients with MDD Depression is the leading cause of disability worldwide,

A two-year extension of the reexamination period by the Japanese Ministry of Health, Labour and Welfare (MHLW) has been discussed and accepted in the First Committee on Drug of MHLW The acceptance is based on the fact that clinical development on pediatrics will be conducted in order to meet the

En toårig forlængelse af markedseksklusiviteten for Lexapro har være diskuteret og accepteret af det japanske Sundheds-, arbejds- og socialministerium (MHLW) Accepten er baseret på det faktum, at et klinisk program i børn vil blive foretaget med henblik på at adressere umødte behov i behandlingen

Valby, Denmark, 2018-03-20 14:01 CET (GLOBE NEWSWIRE) --   Valby, Denmark, 20 March 2018 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

Valby, Denmark, 2018-03-20 14:01 CET (GLOBE NEWSWIRE) -- Valby, Danmark, 20. marts 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at på generalforsamlingen blev bestyrelsens beretning taget til efterretning og årsrapporten blev godkendt. Forslaget om at der for regnskabsåret 2017

Lundbeck vil betale en kontant betaling på EUR 100 millioner og aftalevilkårene inkluderer desuden op til EUR 805 millioner i udviklings-, godkendelses- og salgsmilepæle Foliglurax er den første behandling i sin klasse og påbegyndte klinisk fase II-afprøvning vedrørende Parkinsons sygdom i juli

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson's disease in July 2017 There remains a large